
- Industry news
Industry news
- Category news
Category news
- Reports
- Key trends
- Multimedia
- Journal
- Events
- Suppliers
- Home
- Industry news
Industry news
- Category news
Category news
- Reports
- Key trends
- Multimedia
- Events
- Suppliers
Enifer seeks FDA approval to scale mycoprotein ingredient in US food sector
Key takeaways
- Enifer submits Pekilo mycoprotein for FDA “no questions” status, advancing US market entry.
- The FDA approval is a key step for large-scale US food partnerships, addressing the demand for high-protein, clean label ingredients.
- Pekilo offers a scalable, shelf-stable protein with high nutritional value, ideal for a wide range of food applications.

Enifer has sought US FDA “no questions” status for its fermentation-derived, shelf-stable mycoprotein ingredient (branded Pekilo), which would enable the Finnish biotech firm to position it for large-scale food partnerships in the country. The request for a formal FDA review follows Pekilo’s 2025 self-affirmed GRAS determination.
The filing for FDA “no questions” status is important because it signals regulatory clearance, which is a critical hurdle for food manufacturers looking to integrate new ingredients. While mycoprotein is not yet as widely known or used as other plant-based protein sources like soy or pea protein, it has been steadily gaining attention, particularly within the growing market for functional, high-protein, and hybrid food formulations.

Brands like Quorn have used mycoprotein in consumer products for decades, but Enifer’s innovation is said to offer a more scalable, shelf-stable option. These qualities could make it more attractive for large manufacturers, especially in the US market, which is prioritizing high-protein, functional ingredients.
Regulatory clarity and supply chain resilience
After a period of rapid innovation in alternative proteins, large manufacturers are increasingly prioritizing regulatory clarity and supply chain resilience as adoption criteria for new ingredients, consistent with broader shifts in industry compliance and reformulation pressures.
Clean label and functional protein formulations have also become procurement priorities for major manufacturers seeking stable, scalable inputs beyond traditional plant-based and animal sources.
“Large food manufacturers operate within strict procurement and compliance frameworks,” explains Elisa Arte, head of food R&D at Enifer. “FDA-notified GRAS status removes a key internal barrier, allowing ingredient discussions to move beyond technical sampling into long-term supply planning.”
“At the same time, we are scaling production to ensure consistent, industrial volumes. In a market that has moved past hype and is now focused on unit economics and reliable capacity, regulatory clarity and manufacturing readiness must advance together. This step brings Pekilo into that commercial decision framework.”
Pekilo mycoprotein powder: A shelf-stable ingredient with high protein and fiber content for diverse food formulations.
Proprietary fermentation technology
Enifer develops mycoprotein ingredients using a proprietary fermentation technology, originally pioneered in Finland. The company converts food and agricultural industry side streams into dry, shelf-stable protein and fiber powder, designed for scalable food applications.
Pekilo contains up to 50% protein and 35% fiber, with an optimal amino acid profile and neutral taste and color that allows it to be used across a wide range of applications, including healthy snacking, dairy and meat alternatives and hybrids, and ready-to-eat snacks and baked goods.
Its drop-in functionality helps manufacturers achieve high-protein and high-fiber claims without affecting product sensory profiles, positioning Pekilo as an industrially viable input for manufacturers seeking stable, regulatory-ready ingredients.
Protein formulation demands
As the demand for alternative proteins continues to rise, Pekilo’s entry into the US regulatory process and market could contribute to the expansion of mycoprotein’s role in the food industry. This move aligns with broader trends of food manufacturers seeking stable, clean label ingredients with high nutritional value that are also scalable.
“Demand for protein isn’t slowing, but manufacturers are rethinking where that protein comes from and how it performs in finished products,” says Simo Ellilä, Enifer’s CEO and co-founder. “With regulatory review underway and our 2026 production ramp-up approaching, we are aligning capacity and compliance to support structured, long-term supply relationships in the US market.”
While mycoprotein is not yet ubiquitous across all food products, innovations like Pekilo represent an important step toward increasing its presence and integration into mainstream supply chains.
Upcoming webinars

More per Bite: Turn wellness into market success
Valio
Upcoming events







